Imaging responses to immunotherapy with novel PET tracers
AL Niemeijer, OS Hoekstra, EF Smit… - Journal of Nuclear …, 2020 - Soc Nuclear Med
CONCLUSION PET/CT using novel immune tracers can help monitor and develop ICI therapy.
The biomarker is in its early stage of development, in which validation and qualification …
The biomarker is in its early stage of development, in which validation and qualification …
Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non–small cell lung cancer: results …
…, DW Dumoulin, I Bahce, ALN Niemeijer… - JAMA …, 2019 - jamanetwork.com
Importance Many patients with advanced non–small cell lung cancer (NSCLC) receiving
immunotherapy show primary resistance. High-dose radiotherapy can lead to increased tumor …
immunotherapy show primary resistance. High-dose radiotherapy can lead to increased tumor …
Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials
…, JGJV Aerts, I Bahce, ALN Niemeijer… - The Lancet …, 2021 - thelancet.com
Background Radiotherapy might augment systemic antitumoral responses to immunotherapy.
In the PEMBRO-RT (phase 2) and MDACC (phase 1/2) trials, patients with metastatic non-…
In the PEMBRO-RT (phase 2) and MDACC (phase 1/2) trials, patients with metastatic non-…
[PDF][PDF] Swarm intelligence-enhanced detection of non-small-cell lung cancer using tumor-educated platelets
…, N Sol, S GJG, A Vancura, M Muller, ALN Niemeijer… - Cancer cell, 2017 - cell.com
Blood-based liquid biopsies, including tumor-educated blood platelets (TEPs), have
emerged as promising biomarker sources for non-invasive detection of cancer. Here we …
emerged as promising biomarker sources for non-invasive detection of cancer. Here we …
[PDF][PDF] Detection and localization of early-and late-stage cancers using platelet RNA
…, L Vermunt, A Vancura, M Muller, ALN Niemeijer… - Cancer Cell, 2022 - cell.com
Cancer patients benefit from early tumor detection since treatment outcomes are more
favorable for less advanced cancers. Platelets are involved in cancer progression and are …
favorable for less advanced cancers. Platelets are involved in cancer progression and are …
Study of 89Zr-pembrolizumab PET/CT in patients with advanced-stage non–small cell lung cancer
ALN Niemeijer, DE Oprea-Lager… - Journal of Nuclear …, 2022 - Soc Nuclear Med
The tumor programmed death ligand 1 (PD-L1) proportion score is the current method for
selecting non–small cell lung cancer (NSCLC) patients for single-agent treatment with …
selecting non–small cell lung cancer (NSCLC) patients for single-agent treatment with …
PD-L1 PET/CT Imaging with Radiolabeled Durvalumab in Patients with Advanced-Stage Non–Small Cell Lung Cancer
J Smit, FJ Borm, ALN Niemeijer… - Journal of Nuclear …, 2022 - Soc Nuclear Med
Better biomarkers are needed to predict treatment outcome in non–small cell lung cancer (NSCLC)
patients treated with anti–programmed death-1/programmed death-ligand 1 (PD-1/…
patients treated with anti–programmed death-1/programmed death-ligand 1 (PD-1/…
Quantification of PD-L1 expression with 18F-BMS-986192 PET/CT in patients with advanced-stage non–small cell lung cancer
MC Huisman, ALN Niemeijer… - Journal of Nuclear …, 2020 - Soc Nuclear Med
The aim of this work was to quantify the uptake of 18 F-BMS-986192, a programmed cell death
ligand 1 (PD-L1) adnectin PET tracer, in patients with non–small cell lung cancer. To this …
ligand 1 (PD-L1) adnectin PET tracer, in patients with non–small cell lung cancer. To this …
[HTML][HTML] Association of tumour and stroma PD-1, PD-L1, CD3, CD4 and CD8 expression with DCB and OS to nivolumab treatment in NSCLC patients pre-treated with …
ALN Niemeijer, S Sahba, EF Smit… - British journal of …, 2020 - nature.com
Background Immune checkpoint inhibitors are most beneficial in patients with high tumour
PD-L1 expression. However, the use of PD-L1 expression is not straightforward. We …
PD-L1 expression. However, the use of PD-L1 expression is not straightforward. We …
A Serum Protein Classifier Identifying Patients with Advanced Non–Small Cell Lung Cancer Who Derive Clinical Benefit from Treatment with Immune Checkpoint …
…, K Hummelink, DP Hurkmans, ALN Niemeijer… - Clinical Cancer …, 2020 - AACR
Purpose: Pretreatment selection of patients with non–small cell lung cancer (NSCLC) who
would derive clinical benefit from treatment with immune checkpoint inhibitors (CPIs) would …
would derive clinical benefit from treatment with immune checkpoint inhibitors (CPIs) would …